1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need. While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia. Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years.

GILD has announced the dividend payment and now all eyes will be on CELG and BIIB

Table Of Contents

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success
In-depth Company Analysis and Reports on
1. Acorda Therapeutics - Neurological Pipeline Getting Bigger
- Key Pipeline Drugs
a. CVT -301 (PhIII, OFF episodes of Parkinson's disease)
b. Dalfampridine (PhIII, post-stroke walking deficits)
c. rHIgM22 (Remyelinating mAb, PhI)
d. Glial Growth Factor 2 (neuregulin, PhI, GGF2)
- Other Programs in the Pipeline - Future Uncertain

2. Alexion Pharma - Pipeline Maturity will witness a Strong 2015 for ALXN
- Asfotase alfa (hypophosphatasia, HPP, R) on Track
- Soliris in PNH and aHUS: Growth to Continue
- SOLIRIS BEYOND PNH AND aHUS
- Beyond Soliris
- Other PhII Programs
- Messenger RNA Therapeutics platform from Moderna

3. Amgen - Focus On New Biologics For Larger Market And Exploiting Biologics' Manufacturing Experience For Biosimilars Gain
- Newly Marketed Product: Future Growth
a. Kyprolis
b. BLINCYTO
- Key Pipeline Products and Development
a. Evolocumab (R, PCSK9 Inhibitor, CVD, SC)
b. Ivabradine (R, Chronic Heart Failure):
c. Talimogene laherparepvec
d. Brodalumab (PhIII, moderate-to-severe plaque psoriasis and psoriatic arthritis, PhII, Asthma)
e. Omecamtiv mecarbil (PhIIb, Heartfailure, licensed from Cytokinetics)
f. Romosozumab (PhIII, co-developed with UCB, Postmenopausal Osteoporosis, PMO)
g. AMG 334 (PhIIb, CGRP receptor mAb)
h. Trebananib (PhIII, Ovarian Cancer):
i. AMG 416 (PhIII, secondary hyperparathyroidism in pt with CKD, velcalcetide)
- Failed in Clinical studies
- Biosimilars in Development
- AMGN's Commercial Strategy

4. Biogen Idec - Growth from Newly Launched Products + Clinical Milestones of Novel Pipeline
- Near-Term Key Pipeline Candidates to Watch
- Hemophilia Franchise Offers Long-Term Opportunity
- Anti-CD20 franchise Continues to Grow through Label Expansion of GAZYVA
- NEUROLOGY: LEADERSHIP IN MS AND PORTFOLIO EXPANSION

5. Celgene - Innovative Strategies for Long Term Gains
- Development In Multiple Myeloma Franchise: Strengthening Pipeline
- Other Oncology Drugs
- Inflammation - Pipeline to start contributing to sales by 2015
- Other Products in Early stage for Long Term Growth

6. Gilead Sciences - Poised to Emerge as a Leader in HCV Treatment
- Sovaldi has made the way, Harvoni to take Lead
- Pipeline: Anti-viral Franchise — HCV
- Antiviral Franchise — HIV
- Cardiovascular Program
- Beyond Anti-Virals- Oncology
- Acquisitions In Last Two Years

7. Regeneron - Late-Stage Pipeline Potential - Accelerator for Further Growth
- Label expansion of E ylea in DME, BRVO, and Myopic CNV indication
- Late-Stage Pipeline
- REGN-Sanofi Collaboration

8. Vertex Pharma - From Large Volume Market to Niche Indications - Transformation has Paid
- Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation
- Small But Meaningful Addition in Other Mutations for KALYDECO monotherapy
- CF BACKGROUND
- Beyond CF Not a Priority

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


Download Unlimited Documents from Trusted Public Sources

Hepatitis Statistics and Therapy Market in the UK

  • March 2017
    10 pages
  • Hepatitis  

    Therapy  

    Antiviral  

  • United Kingdom  

View report >

Opioid Market in the US

  • March 2017
    13 pages
  • Opioid  

  • United States  

View report >

Glucagon Like Peptide 1 Receptor Activator Market

  • March 2017
    3 pages
  • Glucagon Like P...  

    Antidiabetics  

    Cardiology  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.